How A Small Molecule Targeting Two Oncogenes Triggers Synthetic Lethality in Leukaemia
Unlike many current leukaemia drugs that target only one pathway, a molecule designed by IACS researchers attacks two essential oncogenes at the same time, leaving cancer cells with no fallback options. As the molecule acts at the DNA-regulation level, it may also bypass some of the resistance mechanisms seen with protein-targeting inhibitors
Read More